Dr. Lal Path Labs Q2 profit soars 28% YoY, EBITDA margin expands; dividend of ₹5/share declared

In the corresponding period of the preceding fiscal year, it had logged a profit of ₹150.6 crore in the same period last year, according to a regulatory filing.

Its consolidated revenue from operations jumped 19.6% YoY to ₹873.9 crore during the quarter under review, compared with ₹730.6 crore in the second quarter of the 2025-26 fiscal year (Q2 FY26).

It delivered a robust top-line growth, marking its strongest Q2 revenue performance in recent years, as per its investor presentation.

At the operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹280 crore in the quarter ended September 30, 2026, registering a 25.1% YoY rise from ₹224 crore in the year-ago period.

Its EBITDA margin expanded by 140 basis points (bps) YoY to 32.1% for the reporting period, in contrast to 30.7% in Q2 FY26.

Its core growth was anchored by strong expansion across sample and patient volumes, the company stated.

The diagnostic and related healthcare tests and services provider saw its patient volume grow 9% YoY to 9 million in Q2 FY27, from 8.2 million in the same period a year ago.

Its number of samples advanced 12.2% YoY to 17.2 million during the quarter under review, compared with 48.8 million in the September quarter of FY26.

Dividend declared

Dr. Lal Path Labs' board of directors also declared its second interim dividend of ₹5 per equity share, at 50%, with a face value of ₹10 each for FY27.

It fixed Wednesday, November 11, 2026, as the record date for the same, further stating that the dividend will be paid within 30 days of its declaration.

What the management said

Commenting on the performance, Shankha Banerjee, Chief Executive Officer of Dr. Lal Path Labs, said: “The healthcare ecosystem is increasingly embracing preventive and precision medicine, reinforcing the critical role of diagnostics in enabling timely clinical decisions. We continue to see growing demand for specialised and high-complexity testing, supported by greater awareness among clinicians and patients alike.”

Banerjee further said that the firm’s focus remains on expanding access to advanced diagnostics by strengthening capabilities in areas such as genomics, oncology, reproductive health, transplant diagnostics, and rare diseases.

He added that investments in scientific expertise, technology, and innovation continue to enhance the company’s ability to serve evolving patient needs.

“As healthcare delivery becomes increasingly data-driven and personalized, we believe our strong scientific foundation, extensive network, and trusted brand position us well to capture the next phase of growth in the diagnostics industry," Banerjee stated.

Dr. Lal Path Labs share performance

Shares of Dr. Lal Path Labs rallied as much as 5.83% to hit an intraday high of ₹2,038 per unit on the National Stock Exchange (NSE) on Wednesday, November 4, following the result announcement.

At around 3:21 PM, the stock was trading 5.44% higher at ₹2,030.50 per equity share. The scrip has advanced more than 5% in the past week and 1% over the month. On a year-to-date (YTD) basis, it has risen 34%.

Dr. Lal Path Labs has a total market capitalisation of ₹34,039.74 crore as of November 4, 2026, according to data on the NSE.